Skip to main content
. Author manuscript; available in PMC: 2012 Aug 15.
Published in final edited form as: Cancer Res. 2012 Jan 5;72(4):854–864. doi: 10.1158/0008-5472.CAN-11-2795

Figure 6.

Figure 6

Enzyme activities (A, C) and metabolite concentrations (B, D) determined by enzymatic assay in tumor extracts (A) Lactate dehydrogenase (LDH) activity and (B) lactate concentration increase in LoVo tumors after treatment. (C) Fumarase activity exhibits a marked decline in HT29 tumors after treatment but there is no significant change for the LoVo tumors. (D) Pyruvate concentration is decreased in LoVo tumors after the second Bevacizumab dose. * p<0.05, ** p<0.01.